Sermorelin Ipamorelin Cjc 1295

Q: What is the recommended diluent for reconstituting secretagogue peptides?

For most cellular assays and preclinical laboratory procedures, sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride injection solution is recommended. The choice depends on the specific sensitivity of the target cellular or tissue culture model.

Q: How should reconstituted peptide stock solutions be stored?

Reconstituted peptide solutions must be kept refrigerated at 2°C to 8°C and protected from light. Under these conditions, stability is maintained for 21 to 28 days. For long-term storage, aliquoting stock solutions to prevent repeated freeze-thaw cycles is required.

Q: Does ipamorelin stimulate cortisol or prolactin secretion in rodent models?

Preclinical data demonstrate that ipamorelin is exceptionally selective for GHSR-1a. Unlike earlier growth hormone secretagogues such as GHRP-2 or GHRP-6, ipamorelin does not trigger significant elevations in cortisol, ACTH, or prolactin levels in animal models at normal experimental concentrations.

Q: Are PX1 Research peptides intended for human consumption or therapeutic use?

No. All products supplied by PX1 Research are strictly engineered and designated for laboratory research use only (in vitro and preclinical animal research). They are not for human or veterinary use, medical therapy, or clinical applications.

Sermorelin, ipamorelin, and CJC-1295 represent three distinct synthetic research compounds designed to stimulate anterior pituitary growth hormone (GH) synthesis and secretion. While sermorelin and CJC-1295 function as growth hormone-releasing hormone (GHRH) receptor agonists, ipamorelin acts as a selective growth hormone secretagogue receptor (GHSR-1a) agonist. In preclinical models, combining GHRH analogs with selective ghrelin mimetics demonstrates synergistic amplification of somatotrope signaling without significantly elevating cortisol or prolactin.

GMP-compliant U.S. facilities

ISO 17025 third-party COAs

100% domestic — no imports

Fast tracked domestic shipping

Shop research peptides

Quick answer

Reviewed by PX1 Research scientific team

Key takeaways

In cell culture and animal models, the regulation of growth hormone (GH) release is governed by a dual-receptor system involving Growth Hormone-Releasing Hormone (GHRH) receptors and Growth Hormone Secretagogue Receptors (GHSR-1a).
[Sermorelin](/research-peptides/sermorelin) is a synthetic 29-amino acid peptide corresponding to the amino-terminal segment of endogenous human Growth Hormone-Releasing Hormone (GHRH 1-29 amide).
[CJC-1295](/research-peptides/cjc-1295-no-dac) is a modified 29-amino acid GHRH analog engineered to overcome the rapid enzymatic degradation that limits native GHRH and [sermorelin](/research-peptides/sermorelin) in vivo.
Unlike GHRH analogs, [ipamorelin](/research-peptides/ipamorelin) is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that belongs to the growth hormone secretagogue (GHS) class.

Biochemical Overview of Growth Hormone Secretagogues

In cell culture and animal models, the regulation of growth hormone (GH) release is governed by a dual-receptor system involving Growth Hormone-Releasing Hormone (GHRH) receptors and Growth Hormone Secretagogue Receptors (GHSR-1a). Synthetic secretagogues are engineered to interact with one or both of these pathways to evaluate cellular mechanisms related to somatotropic signaling, downstream Insulin-like Growth Factor 1 (IGF-1) axis activation, and systemic metabolic regulation.

Laboratory evaluation of secretagogues frequently focuses on comparing short-acting peptides against long-acting modified analogs. Researchers investigating the growth hormone secretagogues overview utilize compounds like sermorelin, CJC-1295, and ipamorelin to analyze pathway specificity, receptor desensitization kinetics, and pulsatile release patterns in vitro and in preclinical animal models. Understanding the precise molecular structures and binding characteristics of these three peptides is essential for designing reproducible laboratory experiments.

Sermorelin: Mechanism and Molecular Structure

Sermorelin is a synthetic 29-amino acid peptide corresponding to the amino-terminal segment of endogenous human Growth Hormone-Releasing Hormone (GHRH 1-29 amide). As a functional GHRH receptor agonist, sermorelin 5mg binds directly to GHRH receptors expressed on the surface of pituitary somatotropes. This binding event triggers a conformational change that activates the stimulatory G-protein (Gs) complex, initiating intracellular signal transduction.

The activation of Gs leads to the stimulation of membrane-bound adenylyl cyclase, which converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP levels subsequently activate Protein Kinase A (PKA), driving the phosphorylation of specific transcription factors and promoting exocytosis of stored GH granules. Because sermorelin retains the biological activity of full-length endogenous GHRH (1-44) while lacking the carboxy-terminal non-essential sequence, it serves as a baseline model for evaluating endogenous GHRH dynamics in isolated tissue cultures and rodent models.

CJC-1295: Modified GHRH Agonism and Kinetic Variations

CJC-1295 is a modified 29-amino acid GHRH analog engineered to overcome the rapid enzymatic degradation that limits native GHRH and sermorelin in vivo. Endogenous GHRH is rapidly cleaved at the Ala2 position by dipeptidyl peptidase IV (DPP-IV). CJC-1295 incorporates specific amino acid substitutions—typically D-Ala2, Gln8, Ala15, and Leu27—that protect the peptide chain from enzymatic cleavage, significantly extending its structural integrity in experimental biological matrices.

Research literature categorizes CJC-1295 into two primary forms: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (also referred to as Modified GRF 1-29). In laboratory experiments utilizing CJC-1295 No DAC 5mg, researchers observe a transient elevation in GH release with a half-life of approximately 30 minutes in rodent models. Conversely, CJC-1295 DAC covalent bonding to serum albumin extends the biological half-life to several days, enabling prolonged activation of the GHRH receptor pathway. This distinction makes CJC-1295 variants valuable tools for studying baseline secretagogue dynamics versus sustained somatotrope stimulation.

Ipamorelin: Selective GHSR-1a Receptor Agonism

Unlike GHRH analogs, ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that belongs to the growth hormone secretagogue (GHS) class. It functions as a selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a), which is the native target for endogenous ghrelin. Activation of GHSR-1a by ipamorelin 5mg operates through a distinct G-protein subunit pathway (Gq/11) rather than the Gs/cAMP pathway activated by GHRH agonists.

Binding of ipamorelin to GHSR-1a stimulates phospholipase C (PLC), resulting in the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the immediate release of intracellular calcium (Ca2+) from the endoplasmic reticulum into the cytoplasm. This localized calcium flux triggers the fusion of GH-containing vesicles with the plasma membrane, driving GH release. A defining characteristic of ipamorelin in preclinical literature is its receptor selectivity; unlike earlier GHRP class compounds, ipamorelin does not significantly induce ACTH, cortisol, aldosterone, or prolactin secretion in rodent models.

Synergistic Signaling: Combining GHRH and GHSR Receptor Activation

When evaluating secretagogues in laboratory settings, researchers frequently investigate dual-receptor co-stimulation models. Preclinical studies indicate that simultaneous activation of GHRH receptors (via sermorelin or CJC-1295) and GHSR-1a receptors (via ipamorelin) produces a synergistic release of GH that exceeds the additive mathematical sum of either compound administered independently.

This molecular synergy occurs through cross-talk between intracellular signaling cascades. cAMP generated by GHRH receptor activation and intracellular calcium mobilized by GHSR-1a activation converge on distinct regulatory steps within somatotrope exocytosis. Furthermore, GHRH agonists enhance the functional expression and binding capacity of GHSR-1a, while GHSR-1a activation dampens somatostatin-mediated inhibition (the primary negative regulator of GH release). Dual formulation systems, such as CJC-1295 No DAC / Ipamorelin blend, are extensively utilized in vitro to study maximum achievable somatotrope response without inducing cell surface receptor desensitization.

Comparative Analysis: Sermorelin, CJC-1295, and Ipamorelin

To select the appropriate research compound or combination for a specific experimental design, investigators must contrast the pharmacodynamic and binding characteristics of each peptide. In comparative studies within the research library, scientists examine how varying amino acid sequences, metabolic half-lives, and signal transduction cascades impact downstream physiological end points such as tissue repair markers and IGF-1 gene expression.

While sermorelin 5mg offers a classic, native-like GHRH signaling profile with rapid clearance, CJC-1295 No DAC 5mg provides enhanced enzymatic resistance while preserving pulsatile secretion. Meanwhile, ipamorelin 5mg targets an entirely separate receptor family (GHSR-1a), generating calcium-dependent secretion without interfering with the hypothalamic-pituitary-adrenal (HPA) axis. Comparing these secretagogues alongside other peptides like GHRP-6 vs GHRP-2 helps delineate the boundaries between broad-spectrum secretagogue activity and highly targeted receptor agonism in preclinical models.

Preclinical Applications in Tissue Repair and Metabolic Research

In animal models and isolated cell cultures, elevated growth hormone levels downstream of GHRH/GHSR agonism promote several metabolic and regenerative processes. GH acts directly on hepatocytes to stimulate the transcription and release of Insulin-like Growth Factor 1 (IGF-1), a primary mediator of systemic anabolic signaling.

Preclinical tissue repair assays indicate that secretagogue-induced IGF-1 elevation enhances fibroblast proliferation, collagen synthesis, and satellite cell activation in skeletal muscle tissue. Researchers examining musculoskeletal repair mechanisms measure rate metrics for cellular migration, wound closure, and protein synthesis following exposure to combination secretagogue regimens. Additionally, animal models of lipid metabolism show that GHRH and GHRP signaling modulates lipolysis in adipose tissue by upregulating hormone-sensitive lipase (HSL) activity, providing a valuable framework for studying metabolic expenditure and energy homeostasis.

Laboratory Reconstitution and Solubilization Protocol

Lyophilized peptide samples must be reconstituted under sterile, controlled conditions prior to administration in cell culture assays or animal models. Standard laboratory procedures dictate utilizing Bacteriostatic Water (containing 0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl), depending on the assay requirements and cellular tolerance.

To reconstitute a lyophilized vial containing sermorelin, CJC-1295, or ipamorelin, allow the vial to reach room temperature before handling. Using a sterile syringe, slowly introduce the diluent against the inner glass wall of the vial to avoid rapid agitation. Gentle swirling or smooth inversion should be applied until the lyophilized cake is fully dissolved into a clear solution. Never vortex peptide solutions, as vigorous mechanical shear forces can cause protein denaturation, aggregation, or loss of secondary structural conformation.

Storage, Stability, and Handling Guidelines

Lyophilized research peptides demonstrate high thermodynamic stability when preserved at low temperatures. Upon receipt, un-reconstituted vials should be stored in a dry, dark environment at -20°C for long-term stability (up to 24 months) or 2°C to 8°C for short-term preservation (up to 90 days). Exposure to ambient heat, light, and humidity accelerates hydrolytic cleavage and oxidation.

Following reconstitution, liquid peptide solutions must be stored strictly at 2°C to 8°C to prevent bacterial growth and enzymatic degradation. Experimental degradation curves indicate that reconstituted GHRH analogs maintain analytical stability for 21 to 28 days when preserved under refrigerated conditions. Repeated freeze-thaw cycles must be strictly avoided for liquid solutions, as ice crystal formation disrupts peptide backbone integrity. For automated high-throughput assays, researchers should aliquot reconstituted stock solutions into single-use micro-centrifuge tubes prior to freezing.

Analytical Purity and Quality Verification

Reliable scientific outcomes require high-purity research materials verified by rigorous, independent analytical methodology. Low-grade or contaminated peptide samples introduce unaccounted variables—such as non-specific cellular toxicity or off-target receptor activation—that invalidate experimental data.

Quality assurance for research peptides relies on three critical analytical standard testing procedures: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish purity mass percentages, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) or ESI-MS to confirm molecular weight and sequence identity, and the Limulus Amebocyte Lysate (LAL) assay to quantify bacterial endotoxin levels. High-purity compounds should consistently yield >98.0% purity by HPLC with endotoxin measurements under 0.05 EU/mg.

PX1 Research Technical Standards and Sourcing

PX1 Research provides USA-synthesized research peptides engineered specifically for demanding in vitro and preclinical research applications. Every lot manufactured undergoes comprehensive analytical testing within ISO 17025 accredited, GMP-compliant facilities to guarantee complete lot traceability and batch consistency.

Principal investigators and procurement officers sourcing through PX1 Research receive lot-specific Certificate of Analysis (COA) documentation detailing full RP-HPLC chromatograms, mass spectrometry verification, and quantitative endotoxin testing. Orders ship directly from domestic facilities located in California and Arizona, utilizing temperature-monitored distribution protocols to preserve chemical stability throughout transit.

Frequently Asked Questions

What is the primary mechanical difference between Sermorelin, CJC-1295, and Ipamorelin?

Sermorelin and CJC-1295 are GHRH (Growth Hormone-Releasing Hormone) receptor agonists that stimulate intracellular cAMP via Gs-protein signaling. Ipamorelin is a selective GHSR-1a (ghrelin receptor) agonist that stimulates intracellular calcium release via Gq/11-protein signaling. They target different receptor families on pituitary somatotropes.

Why are CJC-1295 and Ipamorelin frequently combined in preclinical research?

Combining a GHRH agonist (CJC-1295) with a GHSR agonist (Ipamorelin) creates a dual-receptor synergistic effect. In laboratory models, simultaneous activation of cAMP and calcium signaling pathways yields significantly greater growth hormone release than activating either pathway independently, while simultaneously suppressing somatostatin-mediated inhibition.

How does CJC-1295 No DAC differ from Sermorelin in laboratory assays?

Both are 29-amino acid GHRH analogs, but CJC-1295 No DAC includes four specific amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) designed to resist dipeptidyl peptidase IV (DPP-IV) enzymatic degradation. As a result, CJC-1295 No DAC demonstrates a longer half-life (approx. 30 minutes in rodent models) compared to sermorelin (approx. 8–12 minutes).

What analytical parameters are provided on a PX1 Research COA?

Every PX1 Research Certificate of Analysis (COA) includes lot-specific Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) purity profiles (>98%), Electrospray Ionization or MALDI-TOF Mass Spectrometry (MS) mass identification, and quantitative LAL assay endotoxin analysis (<0.05 EU/mg).

What is the recommended diluent for reconstituting secretagogue peptides?